Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 3/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.36 |
| ▸ | DDO | Q99489 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17417172 | 0.95 | GABRA1 (0.52) | GABRA1GABRB2GABRG2GABRB3TAAR1 | |
| SCHEMBL4886256 | 0.86 | GABRA1 (0.48) | GABRA1GABRB2GABRG2GABRB3TAAR1 | |
| SCHEMBL460389 | 0.85 | GABRA1 (0.52) | GABRA1GABRB2GABRG2GABRB3TAAR1 | |
| SCHEMBL320965 | 0.84 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3TAAR1 | |
| SCHEMBL321361 | 0.84 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3TAAR1 | |
| SCHEMBL245773 | 0.80 | GABRA1 (0.57) | GABRA1GABRB2TAAR1HTR1AMGLL | |
| SCHEMBL27388 | 0.80 | APOBEC3G (0.46) | GABRA1GABRB2GABRG2GABRB3PDCD1 | |
| SCHEMBL9746434 | 0.80 | GABRA1 (0.41) | GABRA1GABRB2GABRG2GABRB3HTR1A | |
| SCHEMBL12280908 | 0.80 | GABRA1 (0.52) | GABRA1GABRB2TAAR1HTR1AKCNH2 | |
| SCHEMBL21205715 | 0.80 | GABRA1 (0.42) | GABRA1GABRB2GABRG2GABRB3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2021-05-06 | — | — | US | disclosed |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-10-20 | — | — | US | disclosed |
| US-20190218227-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-07-18 | — | — | US | disclosed |
| US-10179791-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2019-01-15 | — | — | US | disclosed |
| US-9951084-B2 | Spiro-cyclic amine derivatives as S1P modulators | Abb Vie B.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| EP-3144312-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie B.V. (NL) | 2017-03-22 | — | — | EP | disclosed |
| EP-2590955-B9 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-02-22 | — | — | EP | disclosed |
| US-20160340363-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2590955-B1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-10-12 | — | — | EP | disclosed |
| CN-101918375-A | Benzodiazepinone compounds useful in the treatment of skin conditions | UNIV MICHIGAN | 2010-12-15 | — | — | CN | disclosed |
| EP-2217576-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | The Regents of the University of Michigan (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061916-A2 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| EP-0565488-B1 | Fluorine free titanocenes and their application | CIBA GEIGY AG (CH) | 1999-04-21 | — | — | EP | disclosed |
| US-5340701-A | Photoinitiators | CIBA-GEIGY CORPORATION (US) | 1994-08-23 | — | — | US | disclosed |
| EP-0565488-A1 | Fluorine free titanocenes and their application | CIBA-GEIGY AG (CH) | 1993-10-13 | — | — | EP | disclosed |
| US-5149884-A | Oxidative dehydrogenation of aromatic or aliphatic alcohols in gas phase | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-22 | — | — | US | disclosed |
| EP-0244632-B1 | TUBE BUNDLE REACTOR, ITS USE IN EXOTHERMAL ORGANIC REACTIONS AND PROCESS FOR THE PREPARATION OF KETONES AND ALDEHYDES | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | disclosed |
| US-4224254-A | OXIDATION OF AROMATIC ALCOHOLS, SILVER CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1980-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | GABRA1 2678/4885GABRB2 3723/4885GABRG2 3923/4885 |
| US-20190218227-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | GABRA1 2631/4885GABRB2 3777/4885GABRG2 4003/4885 |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | GABRA1 2678/4885GABRB2 3723/4885GABRG2 3923/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | GABRA1 210/4885GABRB2 231/4885GABRG2 353/4885 |
| US-20160340363-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | GABRA1 2631/4885GABRB2 3777/4885GABRG2 4003/4885 |
| US-10179791-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR3, S1PR1, S1PR2 | GABRA1 2826/4885GABRB2 2431/4885GABRG2 3225/4885 |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | GABRA1 2678/4885GABRB2 3723/4885GABRG2 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.